BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 15466173)

  • 1. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
    Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
    Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
    Yokosawa M; Sonoda Y; Sugiyama S; Saito R; Yamashita Y; Nishihara M; Satoh T; Kumabe T; Yokoyama M; Tominaga T
    Tohoku J Exp Med; 2010 Aug; 221(4):257-64. PubMed ID: 20622491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
    Sugiyama S; Yamashita Y; Kikuchi T; Sonoda Y; Kumabe T; Tominaga T
    Neurol Res; 2008 Nov; 30(9):960-7. PubMed ID: 18671903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal temozolomide drug delivery using convection enhanced delivery.
    Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
    J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
    Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR
    Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
    Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
    Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
    Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S
    Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
    Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
    J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
    Yamashita Y; Krauze MT; Kawaguchi T; Noble CO; Drummond DC; Park JW; Bankiewicz KS
    Neuro Oncol; 2007 Jan; 9(1):20-8. PubMed ID: 17018695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
    Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
    Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
    Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
    Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
    Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
    BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
    Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
    Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.